Stealth BioTherapeutics Corp (NASDAQ:MITO) – Stock analysts at Jefferies Financial Group issued their FY2023 earnings per share (EPS) estimates for Stealth BioTherapeutics in a note issued to investors on Thursday, August 15th. Jefferies Financial Group analyst M. Raycroft forecasts that the company will post earnings of ($0.01) per share for the year.
Stealth BioTherapeutics (NASDAQ:MITO) last issued its earnings results on Wednesday, August 14th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04.
Shares of NASDAQ:MITO opened at $10.79 on Monday. Stealth BioTherapeutics has a twelve month low of $10.70 and a twelve month high of $20.99. The stock’s 50 day moving average price is $12.17. The firm has a market capitalization of $423.51 million and a price-to-earnings ratio of -7.65.
An institutional investor recently bought a new position in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC purchased a new position in shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned approximately 0.18% of Stealth BioTherapeutics at the end of the most recent quarter. 0.73% of the stock is currently owned by hedge funds and other institutional investors.
Stealth BioTherapeutics Company Profile
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.